

## Medical Coverage Policy | Extracorporeal Shock Wave Treatment for Plantar Fasciitis and Other Musculoskeletal Conditions



**EFFECTIVE DATE:** 10|01|2015

**POLICY LAST UPDATED:** 11|05|2019

### OVERVIEW

Extracorporeal shock wave therapy (ESWT) is a noninvasive method that may be used to treat pain using shock waves or sound waves that are directed from outside the body onto the area to be treated, e.g., the heel in the case of plantar fasciitis. Shock waves may be generated at high- or low-energy intensity, and treatment protocols may include more than one treatment. ESWT has been investigated for use in a variety of musculoskeletal conditions.

### MEDICAL CRITERIA

Not applicable

### PRIOR AUTHORIZATION

Not applicable

### POLICY STATEMENT

#### BlueCHiP for Medicare

Extracorporeal shock wave therapy, using either a high- or low-dose protocol or radial ESWT, is not covered as a treatment of musculoskeletal conditions, including but not limited to plantar fasciitis; tendinopathies including tendinitis of the shoulder, tendinitis of the elbow (lateral epicondylitis), Achilles tendinitis, and patellar tendinitis; spasticity; stress fractures; delayed union and nonunion of fractures; and avascular necrosis of the femoral head, as the evidence is insufficient to determine the effects of the technology on health outcomes.

#### Commercial Products

Extracorporeal shock wave therapy, using either a high- or low-dose protocol or radial ESWT, is considered not medically necessary as a treatment of musculoskeletal conditions, including but not limited to plantar fasciitis; tendinopathies including tendinitis of the shoulder, tendinitis of the elbow (lateral epicondylitis), Achilles tendinitis, and patellar tendinitis; spasticity; stress fractures; delayed union and nonunion of fractures; and avascular necrosis of the femoral head, as the evidence is insufficient to determine the effects of the technology on health outcomes.

### COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

### BACKGROUND

#### CHRONIC MUSCULOSKELETAL CONDITIONS

Chronic musculoskeletal conditions (eg, tendinitis) can be associated with a substantial degree of scarring and calcium deposition. Calcium deposits may restrict motion and encroach on other structures, such as nerves and blood vessels, causing pain and decreased function. One hypothesis is that disruption of calcific deposits by shock waves may loosen adjacent structures and promote resorption of calcium, thereby decreasing pain and improving function.

#### Plantar Fasciitis

Plantar fasciitis is a very common ailment characterized by deep pain in the plantar aspect of the heel, particularly on arising from bed. While the pain may subside with activity, in some patients the pain may persist, interrupting activities of daily living. On physical examination, firm pressure will elicit a tender spot over the medial tubercle of the calcaneus. The exact etiology of plantar fasciitis is unclear, although repetitive injury is suspected. Heel spurs are a common associated finding, although it has never been proven that heel spurs cause the pain and asymptomatic heel spurs can be found in up to 10% of the population.

### **Tendinitis and Tendinopathies**

Common tendinitis and tendinopathy syndromes are:

- Lateral epicondylitis (“tennis elbow”)
- Shoulder tendinopathy
- Achilles tendinopathy
- Patellar tendinopathy (“jumper's knee”)

### **Fracture Nonunion and Delayed Union**

The following criteria are used to define fracture nonunion:

- At least 3 months have passed since the date of fracture;
- Serial radiographs have confirmed that no progressive signs of healing have occurred;
- The fracture gap is 1 cm or less; and
- The patient can be adequately immobilized and is of an age likely to comply with non-weight bearing.

Delayed union can be defined as a decelerating healing process, as determined by serial radiographs, together with a lack of clinical and radiologic evidence of union, bony continuity, or bone reaction at the fracture site for no less than 3 months from the index injury or the most recent intervention. (In contrast, nonunion serial radiographs show no evidence of healing.)

### **Other Musculoskeletal and Neurologic Conditions**

Other musculoskeletal conditions include medial tibial stress syndrome, osteonecrosis (avascular necrosis) of the femoral head, coccydynia, and painful stump neuromas. Neurologic conditions include spasticity, which refers to a motor disorder characterized by increased velocity-dependent stretch reflexes. It is one characteristic of upper motor neuron dysfunction, which may be due to a variety of pathologies.

### **Treatment**

Most cases of plantar fasciitis are treated with conservative therapy, including rest or minimization of running and jumping, heel cups, and nonsteroidal-anti-inflammatory drugs. Local steroid injection may also be used. Improvement may take up to 1 year in some cases. For tendinitis and tendinopathy syndromes, conservative treatment often involves rest, activity modifications, physical therapy, and anti-inflammatory medications.

### ***Extracorporeal Shock Wave Therapy***

Also known as orthotripsy, extracorporeal shock wave therapy (ESWT) has been available since the early 1980s for the treatment of renal stones and has been widely investigated for the treatment of biliary stones. ESWT uses externally-applied shock waves to create a transient pressure disturbance, which disrupts solid structures, breaking them into smaller fragments, thus allowing spontaneous passage and/or removal of stones. The mechanism by which ESWT might have an effect on musculoskeletal conditions is not well-defined.

Other mechanisms are also thought to be involved in ESWT. Physical stimuli are known to activate endogenous pain control systems, and activation by shock waves may “reset” the endogenous pain receptors. Damage to endothelial tissue from ESWT may result in increased vessel wall permeability, causing increased diffusion of cytokines, which may in turn promote healing. Microtrauma induced by ESWT may promote

angiogenesis and thus aid in healing. Finally, shock waves have been shown to stimulate osteogenesis and promote callous formation in animals, which is the rationale for trials of ESWT in delayed union or nonunion of bone fractures.

There are 2 types of ESWT: focused and radial. Focused ESWT sends medium- to high-energy shockwaves of single pressure pulses lasting microseconds, directed on a specific target using ultrasound or radiographic guidance. Radial ESWT (RSW) transmits low- to medium-energy shockwaves radially over a larger surface area. The Food and Drug Administration (FDA) approval was first granted in 2002 for focused ESWT devices and in 2007 for RSW devices.

Currently, 6 focused ESWT devices have been approved by FDA through the premarket approval process for orthopedic use:

- OssaTron® device (HealthTronics) - Approval date: 2000. Delivery system: Electrohydraulic. Indications: chronic proximal plantar fasciitis, i.e., pain persisting >6 months and not responding to conservative management; lateral epicondylitis
- Epos™ Ultra (Dornier) - Approval date: 2002. Delivery system: Electromagnetic. Indications: plantar fasciitis.
- SONOCUR® Basic (Siemens) - Approval date: 2002. Delivery system: Electromagnetic. Indications: chronic lateral epicondylitis (unresponsive to conservative therapy for >6 months)
- Orthospec™ Orthopedic ESWT (Medispec) - Approval date: 2005. Delivery system: Electrohydraulic spark-gap. Indications: Chronic proximal plantar fasciitis in patients ≥18 years of age.
- Orbasone™ Pain Relief System (Orthometrix) - Approval date: 2005. Delivery system: High-energy sonic wave. Indications: Chronic proximal plantar fasciitis in patients ≥18 years of age.
- Duolith® SD1 Shock Wave Therapy Device (Storz Medical AG) - Approval date: 2016. Delivery system: Electromagnetic. Indications: Chronic proximal plantar fasciitis in patients ≥18 years of age with history of failed alternative conservative therapies >6 mo

Both high-dose and low-dose protocols have been investigated. A high-dose protocol consists of a single treatment of high-energy shock waves (1300mJ/mm<sup>2</sup>). This painful procedure requires anesthesia and is performed in a hospital or ambulatory surgery center. A low-dose protocol consists of multiple treatments, spaced one week to one month apart, in which a lower dose of shock waves is applied. This protocol does not require anesthesia and is usually used in the office. The FDA-labeled indication for the OssaTron and Epos Ultra devices specifically describes a high-dose protocol, while the labeled indication for the SONOCUR device describes a low-dose protocol.

In 2007, Dolorclast® (EMS Electro Medical Systems), a radial ESWT, was approved by FDA through the premarket approval process. Radial ESWT is generated ballistically by accelerating a bullet to hit an applicator, which transforms the kinetic energy into radially expanding shock waves. Radial ESWT is described as an alternative to focused ESWT and is said to address larger treatment areas, thus providing potential advantages in superficial applications like tendinopathies. The FDA-approved indication is for the treatment of patients 18 years and older with chronic proximal plantar fasciitis and a history of unsuccessful conservative therapy.

The evidence is insufficient to determine the effects of extracorporeal shock wave therapy on health outcomes for the following individuals who have:

- plantar fasciitis
- lateral epicondylitis
- shoulder tendinopathy
- Achilles tendinopathy
- patellar tendinopathy

- medial tibial stress syndrome
- osteonecrosis of the femoral head
- nonunion or delayed union
- spasticity

### **CODING**

The following CPT codes are not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products:

**28890** Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia.

**0101T** Extracorporeal shock wave involving musculoskeletal system, not otherwise specified; high energy

**0102T** Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle

There is no specific CPT code for low-energy or radial ESWT. The unlisted CPT code for general musculoskeletal procedure (20999) should be used.

### **RELATED POLICIES**

BlueCHiP for Medicare National and Local Coverage Determinations  
New Technology

### **PUBLISHED**

Provider Update, 2020

Provider Update, January 2019

Provider Update, January 2018

Provider Update, January 2017

Provider Update, August 2015

### **REFERENCES**

1. Sun J, Gao F, Wang Y, et al. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: A meta-analysis of RCTs. *Medicine (Baltimore)*. Apr 2017;96(15):e6621. PMID 28403111
2. Lou J, Wang S, Liu S, et al. Effectiveness of extracorporeal shock wave therapy without local anesthesia in patients with recalcitrant plantar fasciitis: a meta-analysis of randomized controlled trials. *Am J Phys Med Rehabil*. Aug 2017;96(8):529-534. PMID 27977431
3. Yin MC, Ye J, Yao M, et al. Is extracorporeal shock wave therapy clinical efficacy for relief of chronic, recalcitrant plantar fasciitis? A systematic review and meta-analysis of randomized placebo or active-treatment controlled trials. *Arch Phys Med Rehabil*. Aug 2014;95(8):1585-1593. PMID 24662810
4. Dizon JN, Gonzalez-Suarez C, Zamora MT, et al. Effectiveness of extracorporeal shock wave therapy in chronic plantar fasciitis: a meta-analysis. *Am J Phys Med Rehabil*. Jul 2013;92(7):606-620. PMID 23552334
5. Aqil A, Siddiqui MR, Solan M, et al. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: a meta-analysis of RCTs. *Clin Orthop Relat Res*. Nov 2013;471(11):3645-3652. PMID 23813184
6. Zhiyun L, Tao J, Zengwu S. Meta-analysis of high-energy extracorporeal shock wave therapy in recalcitrant plantar fasciitis. *Swiss Med Wkly*. Jul 07 2013;143:w13825. PMID 23832373
7. Gollwitzer H, Saxena A, DiDomenico LA, et al. Clinically relevant effectiveness of focused extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: a randomized, controlled multicenter study. *J Bone Joint Surg Am*. May 6 2015;97(9):701-708. PMID 25948515
8. Food and Drug Administration. Summary of safety and effectiveness: Orbasone Pain Relief System. 2005; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf4/P040039b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040039b.pdf). Accessed June 4, 2018.

9. Food and Drug Administration. Summary of safety and effectiveness data: Orthospec™ Orthopedic ESWT. 2005; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf4/P040026b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040026b.pdf). Accessed June 4, 2018.
10. Gerdesmeyer L, Frey C, Vester J, et al. Radial extracorporeal shock wave therapy is safe and effective in the treatment of chronic recalcitrant plantar fasciitis: results of a confirmatory randomized placebo-controlled multicenter study. *Am J Sports Med.* Nov 2008;36(11):2100-2109. PMID 18832341
11. Gollwitzer H, Diehl P, von Korff A, et al. Extracorporeal shock wave therapy for chronic painful heel syndrome: a prospective, double blind, randomized trial assessing the efficacy of a new electromagnetic shock wave device. *J Foot Ankle Surg.* Sep-Oct 2007;46(5):348-357. PMID 17761319
12. Greve JM, Grecco MV, Santos-Silva PR. Comparison of radial shockwaves and conventional physiotherapy for treating plantar fasciitis. *Clinics (Sao Paulo).* Feb 2009;64(2):97-103. PMID 19219314
13. Ibrahim MI, Donatelli RA, Schmitz C, et al. Chronic plantar fasciitis treated with two sessions of radial extracorporeal shock wave therapy. *Foot Ankle Int.* May 2010;31(5):391-397. PMID 20460065
14. Ibrahim MI, Donatelli RA, Hellman M, et al. Long-term results of radial extracorporeal shock wave treatment for chronic plantar fasciopathy: A prospective, randomized, placebo-controlled trial with two years follow-up. *J Orthop Res.* Jul 2017;35(7):1532-1538. PMID 27567022
15. Radwan YA, Mansour AM, Badawy WS. Resistant plantar fasciopathy: shock wave versus endoscopic plantar fascial release. *Int Orthop.* Oct 2012;36(10):2147-2156. PMID 22782376
16. Eslamian F, Shakouri SK, Jahanjoo F, et al. Extra corporeal shock wave therapy versus local corticosteroid injection in the treatment of chronic plantar fasciitis, a single blinded randomized clinical trial. *Pain Med.* Sep 2016;17(9):1722-1731. PMID 27282594
17. Lai TW, Ma HL, Lee MS, et al. Ultrasonography and clinical outcome comparison of extracorporeal shock wave therapy and corticosteroid injections for chronic plantar fasciitis: A randomized controlled trial. *J Musculoskelet Neuronal Interact.* Mar 1 2018;18(1):47-54. PMID 29504578
18. Cinar E, Saxena S, Uygur F. Combination therapy versus exercise and orthotic support in the management of pain in plantar fasciitis: a randomized controlled trial. *Foot Ankle Int.* Apr 2018;39(4):406-414. PMID 29327602
19. Park JW, Yoon K, Chun KS, et al. Long-term outcome of low-energy extracorporeal shock wave therapy for plantar fasciitis: comparative analysis according to ultrasonographic findings. *Ann Rehabil Med.* Aug 2014;38(4):534-540. PMID 25229032
20. Food and Drug Administration. Summary of safety and effectiveness: SONOCUR® Basic. 2002; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf/P010039b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf/P010039b.pdf). Accessed June 4, 2018.
21. Rompe JD, Decking J, Schoellner C, et al. Repetitive low-energy shock wave treatment for chronic lateral epicondylitis in tennis players. *Am J Sports Med.* Apr-May 2004;32(3):734-743. PMID 15090392
22. Food and Drug Administration. Summary of safety and effectiveness: HealthTronics™ OssaTron 2000; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf/P990086b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf/P990086b.pdf). Accessed June 4, 2018.
23. Haake M, Konig IR, Decker T, et al. Extracorporeal shock wave therapy in the treatment of lateral epicondylitis : a randomized multicenter trial. *J Bone Joint Surg Am.* Nov 2002;84-A(11):1982-1991. PMID 12429759
24. Buchbinder R, Green SE, Youd JM, et al. Shock wave therapy for lateral elbow pain. *Cochrane Database Syst Rev.* Oct 19 2005(4):CD003524. PMID 16235324
25. Dingemans R, Randsdorp M, Koes BW, et al. Evidence for the effectiveness of electrophysical modalities for treatment of medial and lateral epicondylitis: a systematic review. *Br J Sports Med.* Jun 2014;48(12):957-965.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

